One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Fresenius Medical Care AG (FMS): score, valuation & FAQ
Fresenius Medical Care AG (FMS) is a Medical Care Facilities company that scores 72.6 out of 100 on the Bull Rankings quality-growth model — a solid, above-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are P/E (A-) and PEG (B+). On valuation, FMS sits about 57% below our discounted-cash-flow fair value (a margin of safety) — the current price implies roughly -6% annual free-cash-flow growth over the next decade.
Is FMS a good stock to buy?
Bull Rankings scores FMS 72.6 out of 100 on its quality-growth model, which is a solid, above-average reading. That is driven by P/E (A-) and PEG (B+). A score is a quantitative screen of Fresenius Medical Care AG's fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does FMS score 72.6 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). FMS earns its highest marks on P/E (A-) and PEG (B+). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is FMS overvalued or undervalued?
Based on $24.11, FMS sits about 57% below our discounted-cash-flow fair value (a margin of safety) — the current price implies roughly -6% annual free-cash-flow growth over the next decade. It trades at a 13.0x× P/E (graded A-). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in FMS?
The bear case focuses on the modest 13× P/E multiple, which, while not excessive, reflects market skepticism about growth sustainability given the 0.82 beta and a 0.78 debt‑to‑equity ratio that could limit future cap‑ex. A slowdown in dialysis demand or tighter reimbursement could compress margins, and a breach of the 10‑year reverse‑DCF implied –6% free‑cash‑flow growth would invalidate the current valuation. Confirmation would be a miss on revenue growth or a margin contraction beyond the current 23.6% level.
New to these metrics? The guides explain free cash flow, how the score works, and more in the learn hub — or run another name through the screener.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.